A 52-year-old man with a 10-year history of Type 2 diabetes mellitus presents with a 6-week history of depressed mood, loss of interest in his business, and persistent fatigue despite adequate sleep. He reports difficulty concentrating and making decisions at work. His wife notes he appears withdrawn and has stopped attending social gatherings. He denies suicidal thoughts. His HbA1c is 8.2%, blood pressure is 138/88 mmHg, and BMI is 31 kg/m². He is currently on metformin and lisinopril. Mental status examination reveals depressed affect, psychomotor slowing, and poor insight. What is the most appropriate initial management strategy for this patient?

Explanation

## Clinical Context and Diagnostic Approach This patient presents with: - **Core MDD symptoms:** depressed mood (6 weeks), anhedonia (loss of interest), fatigue - **Cognitive symptoms:** poor concentration, indecision - **Behavioral changes:** social withdrawal, reduced activity - **Comorbidities:** Type 2 diabetes (suboptimal control, HbA1c 8.2%), hypertension, obesity **Key Point:** Depression in diabetic patients is bidirectional — depression worsens glycemic control, and poor glycemic control exacerbates depression. Both conditions must be addressed simultaneously. ### Why Sertraline + Diabetes Optimization Is Optimal ```mermaid flowchart TD A[MDD + Type 2 DM]:::outcome --> B{Concurrent treatment needed?}:::decision B -->|Yes| C[Start SSRI + optimize diabetes]:::action B -->|No| D[Delay psychiatric treatment]:::urgent C --> E[Sertraline 50 mg daily]:::action C --> F[Insulin initiation if HbA1c > 8%]:::action E --> G[Improved mood + better glycemic control]:::outcome F --> G G --> H[Reduced cardiovascular risk]:::outcome ``` **High-Yield:** SSRIs are the preferred agents in diabetic patients because they: - Do not cause weight gain (unlike TCAs or atypical antipsychotics) - Do not impair glucose metabolism - Have neutral or beneficial metabolic effects - Sertraline has the best evidence in diabetic depression ### Comparison of Pharmacological Options in Diabetic Depression | Agent | Efficacy in MDD | Metabolic Effect | Weight Change | Neuropathy | Recommendation | |-------|-----------------|------------------|---------------|------------|----------------| | Sertraline (SSRI) | Excellent | Neutral/beneficial | Neutral | No | **First-line** | | Amitriptyline (TCA) | Excellent | Impairs glucose control | Weight gain | Yes (benefit) | Avoid in diabetes | | Fluoxetine (SSRI) | Excellent | Neutral | Weight loss | No | Alternative first-line | | Venlafaxine (SNRI) | Excellent | Neutral | Neutral | Possible benefit | Alternative | | Bupropion | Good | Neutral | Weight loss | No | Alternative (caution in HTN) | **Clinical Pearl:** In diabetic patients with depression, SSRIs (especially sertraline) are preferred over TCAs because TCAs can impair glucose metabolism and cause weight gain—both detrimental in Type 2 diabetes. Amitriptyline's benefit for neuropathic pain does not outweigh its metabolic risks in this patient. **Mnemonic: SSRI-DM** — SSRIs are Safe, Sertraline preferred, Insulin/optimization concurrent, Reduce cardiovascular risk, Improve both mood and metabolic control. ### Integrated Management 1. **Psychiatric:** Sertraline 50 mg daily (start low, titrate to 100–150 mg over 4–6 weeks) 2. **Endocrine:** Insulin initiation (HbA1c 8.2% indicates inadequate control on metformin alone) 3. **Lifestyle:** Counseling on diet, exercise, sleep hygiene 4. **Monitoring:** Reassess mood at 4 weeks, HbA1c at 3 months **Warning:** Do NOT delay psychiatric treatment pending diabetes optimization — they must proceed in parallel. Depression itself impairs self-care and glycemic control.